- Home
- AGM vs DVAX Comparison
AGM vs DVAX Comparison
Compare AGM & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGM
- DVAX
- Stock Information
- Founded
- AGM 1987
- DVAX 1996
- Country
- AGM United States
- DVAX United States
- Employees
- AGM N/A
- DVAX N/A
- Industry
- AGM Finance Companies
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- AGM Finance
- DVAX Health Care
- Exchange
- AGM Nasdaq
- DVAX Nasdaq
- Market Cap
- AGM 2.0B
- DVAX 1.7B
- IPO Year
- AGM N/A
- DVAX 2004
- Fundamental
- Price
- AGM $197.16
- DVAX $12.68
- Analyst Decision
- AGM Hold
- DVAX Buy
- Analyst Count
- AGM 1
- DVAX 2
- Target Price
- AGM $205.00
- DVAX $23.00
- AVG Volume (30 Days)
- AGM 37.5K
- DVAX 1.7M
- Earning Date
- AGM 02-21-2025
- DVAX 02-20-2025
- Dividend Yield
- AGM 2.84%
- DVAX N/A
- EPS Growth
- AGM 0.71
- DVAX N/A
- EPS
- AGM 15.55
- DVAX 0.15
- Revenue
- AGM $347,661,000.00
- DVAX $260,810,000.00
- Revenue This Year
- AGM N/A
- DVAX $22.13
- Revenue Next Year
- AGM $6.65
- DVAX $19.91
- P/E Ratio
- AGM $12.70
- DVAX $83.61
- Revenue Growth
- AGM 2.91
- DVAX N/A
- 52 Week Low
- AGM $169.17
- DVAX $9.74
- 52 Week High
- AGM $217.60
- DVAX $14.30
- Technical
- Relative Strength Index (RSI)
- AGM 48.51
- DVAX 50.85
- Support Level
- AGM $179.15
- DVAX $12.21
- Resistance Level
- AGM $196.86
- DVAX $12.74
- Average True Range (ATR)
- AGM 4.26
- DVAX 0.36
- MACD
- AGM 0.75
- DVAX -0.04
- Stochastic Oscillator
- AGM 80.20
- DVAX 57.39
About AGM Federal Agricultural Mortgage Corporation
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Rural Utilities, Renewable Energy, Funding, Investments, and Corporate. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.